Expect a productive 2024 for early pipeline assets

M N 27 Feb 2024 CMB International Global Markets | Equity Research | Company Update BeiGene (BGNE US) Expect a productive 2024 for early pipeline assets  Strong sales momentum of zanubrutinib eased market concerns. In 4Q23, Target Price US$268.20 BeiGene recorded total product sales of US$631mn (+6% QoQ or +86% YoY). (Previous TP US$295.67) Zanubrutinib (zanu) maintained strong sales momentum, with revenue increasing Up/Downside 67.4% 15% QoQ or 135% YoY to US$413mn, mainly driven by market share gains in ...